|Table of Contents|

Experimental study on the therapy of pancreatic cancer by combining methionine encephalin with low dose naltrexone

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
22-27
Research Field:
Publishing date:

Info

Title:
Experimental study on the therapy of pancreatic cancer by combining methionine encephalin with low dose naltrexone
Author(s):
Wang Dalu1; Du Lin1; Meng Qi1; Ge Yang1; Shan Fengping2; Su Qi1
1.Shengjing Hospital of China Medical University,Liaoning Shenyang 110004,China;2.China Medical University,Liaoning Shenyang 110122,China.
Keywords:
methionine encephalin; naltrexone; pancreatic cancer; opioid receptor
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2018.01.006
Abstract:
Objective：Compare MENK，LDN and the combine of MENK and NTX in vivo and in vitro，evaluate the effect of MENK，LDN and combining MENK with NTX on the inhibition of pancreatic cancer. Methods：In vitro，MTS method for detecting the inhibition of pancreatic cell proliferation in different experimental groups.In vivo，by the model of the pancreatic tumor-bearing mice，evaluated the effect of different experimental groups on inhibition of pancreatic cancer.Assay the expression of opioid receptor protein in pancreatic tissue of the model of the pancreatic tumor-bearing mice by the mothed of WB.Analyze the proliferation of cytometry lymphocyte subsets (CTL，Treg，NK，γδT) of tumor-bearing mice by FCM.Results：In vitro，it's strongest of MENK to inhibit pancreatic cancer cells at a concentration of 10-6 mol/L.It's strongest of NTX to inhibit pancreatic cancer cells at a concentration of 10-5 mol/L.Comparatively，MENK has a more significant role.In vivo，MENK combining with NTX group compared with control group，tumor suppressor rate increased after 48 hour sand after 96 hours，got the highest tumor suppressor rate comparing with MENK and NTX group.In vivo，in once every 24 hours of delivery mode，the best inhibiting tumor dose of MENK was 20 milligrams per kilogram of body weight. In once every 96 hours of delivery mode，the best inhibiting tumor dose of NTX was 5 milligrams per kilogram of body weight.MENK in once every 24 hours of delivery mode，at a dose of 20 milligrams per kilogram of body weight，combining with NTX in once every 96 hours of delivery mode，at a dose of 5 milligrams per kilogram of body weight had the highest tumor suppressor rate.Detect the opioid receptor protein expression of tumor tissue by WB.The opioid receptor expression of NTX and MENK combining with NTX group in tumor tissue increased.Compared with MENK combing with NTX group，NTX group had a higher opioid receptor expression.Detect lymphocyte subsets proliferation of tumor-bearing mice by FCM.MENK，NTX and MENK combining with NTX group can all promote lymphocyte subsets (CTL，NK，γδT) proliferation，compared with the control group.MENK，NTX and MENK combining with NTX group can all inhibit lymphocyte subsets (CTL，NK，γδT) proliferation，compared with the control group.Conclusion：In vitro，both MENK and NTX can inhibit pancreatic cancer cell proliferation，comparatively，MENK has a more significant role.MENK combined with NTX to inhibit pancreatic cancer cell proliferation，NTX administered in a synergistic effect after 72 hours.NTX can increase the protein expression of opioid receptors in tumor tissue of tumor-bearing mice.In vivo，both MENK and NTX can promote the proliferation of CTL，NK and γδT cell.Both MENK and NTX can inhibit the proliferation of Treg cells.MENK combining with NTX have synergistic effect on the proliferation of CTL，NK and γδT cell.

References:

［1］Meng Y，Gao X，Chen W，et al. Methionine enkephalin (MENK) mounts antitumor effect via regulating dendritic cells (DCs)［J］. International Immunopharmacology，2017，44：61-71.
［2］Zagon IS，Staci D. Opioid growth factor(OGF) inhibits human pancreatic cancer transplanted into nude mice［J］. Cancer Letters，2014，112：167.
［3］Renee N Donahue，Zagon IS. Low-dose naltrexone targets the opioid growth factor opioid growth factor receptor pathway to inhibit cell proliferation：mechanistic evidence from a tissue culture model［J］.Experimental Biology and Deicine,2008，236：1036-1050.
［4］Wybrna TJ，Famaey PJ，Gonaerts A.Receptors for morphine and MENK on human t lymphocytes：the two hits opioid lymphocyte receptor hypothesis.in"new trends in human immunology and cancer therapy"［M］. Publishers Paris，1998：48-55.
［5］Zhang KY,Dou J,Shan FP.Immunoregulation and application of methionine endorphins［J］.Chin J Immunology,2017，33(5)：788-792.［张克莹，都健，单风平.蛋氨酸脑啡肽的免疫调节作用及应用新进展［J］.中国免疫学杂志，2017，33(5)：788-792.］
［6］Li X，Meng Y，Plotnikoff NP，et al.Methionine encephalin(MENK) inhibits tumor growth through regulating CD4+ Foxp3+ regulatory T cells(Tregs) in mice［J］.Cancer Biol Ther，2015，16(3)：351-376.
［7］Wang DM，Wang GC，Yang J，et al. Inhibition of the growth of human melanoma cells by methionine enkephalin［J］. Molecular Medicine Reports，2016，14(6)：5521.
［8］Zagon IS，Ruth TB，Mclauqldin PJ. Nuclecytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium［J］. Anat Rec A Discov Mol Cell Evol Cell Evol Biol，2005，282(1)：24-37.
［9］Zhao D，Plotnikoff N，Griffin N，et al. Methionine enkephalin，its role in immunoregulation and cancer therapy［J］. International Immunopharmacology，2016，37：59-64.
［10］Zagon IS，Staci D. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture［J］. Am J Physiol Regulatory Integrative Comp Physiol，2013，271：511-518.
［11］Hitoshi Ohmori，Kiyomu Fujii. Menthionine-enkephalin secreted by human colorectal cancer cells suppresses T lymphocytes［J］. Cancer Sci，2009，100(3)：497-502.
［12］Fan Cheng，Patricia J McLaughlin.The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer［J］.Molecular Cancer，2008，7(5)：1-12.
［13］Renee N Donahue，Patricia J Mclaughin.Low-dose naltrexone suppresses ovarian cancer 23 and exhibits enhanced inhibition in combination with Cisplatin［J］.Experimental Biology and Medicine，2011，236：883-892.
［14］Renee N Donahue，Zagon IS. Low-dose naltrexone targets the opioid growth factor opioid growth factor receptor pathway to inhibit cell proliferation：Mechanistic evidence from a tissue culture model［J］.Experimental Biology and Medicine，2013，236：1036-1050.
［15］Patricia J Mc Laughlin，Zagon IS. The opioid growth factor-opioid growth factor receptor axis：Homeostatic regulator of cell proliferationand its implications for health and disease［J］.Biochemical Pharmacology，2012，84：746-755.
［16］Banchereau J，Briere F，Caux C，et al. Immunology of dendritic cells［J］.Annu Rev Immunol，2005，18：767-771.
［17］Li PF，Hao YS，Zhang FX.Signaling pathway involved in methionine-enkephalin promoted survival of lymphocytes infected by simian immuno-deficiency in the early stage in vitro［J］.Int Immunopharmacol，2004，4(1)：79-90.
［18］Kowalski J. Immunologic action of［Met5］ enkephalin fragments［J］. European J Pharmacology，2005，347(1)：95-99.
［19］Belgrade，Yugoslavia.Peripheral effects of methionine-enkephlin on inflammatory reactions and behavior in the rat［J］.Neuroimmunomodulation，2008，8(2)：70-75.
［20］Silvia Franchi，Sarah Moretti，Mara Castelli，et al.Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages［J］.Brain Behavior and Immunity，2012，26：480-488.
［21］Sandeep Kumar，Hojun Song. Exposure to exogenous enkephalins disrupts reproductive development in the eastern lubber grasshopper，roma lea microptera (insecta：orthoptera)［J］.Plos One，2012，7(11)：1-5.
［22］Zagon IS，James D Wylie，Torre B Ruth,et al. Naltrexone，an opioid antagonist，facilitates reepithelialization of the cornea in diabetic rat［J］.Diabetic Corneal Repair And Opioids，2002，51：3055-3062.
［23］Norman Brown，Jaak Panksepp.Low-dose naltrexone for disease prevention and quality of life［J］.Medical Hypotheses，2009，72：333-337.
［24］Patricia J Mclaughlin，Zagon IS.Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer［J］.Expert Reviews，2012，6(2)：133-135.

Memo

Memo:
-
Last Update: 2017-11-30